The humanized TriKE CD16/IL-15/CD33 is currently under evaluation in a phase I/II trial for the treatment of high-risk myelodysplastic syndromes, refractory/relapsed AML and advanced systemic mastocytosis (NCT03214666). The gene discussed is CD33; the disease is acute myeloid leukemia.